Objective:To investigate whether serum interleukin-8(IL-8)can be used as a predictor to evaluate the efficacy of pegylated interferon-α(PEG-IFN-α)antiviral therapy in HBeAg-positive chronic hepatitis B(CHB)patients.Methods:53 HBeAg-positive CHB patients received PEG-IFN-α antiviral therapy for 48 weeks.Serum IL-8 levels were compared between patients who achieved non-response and patients who achieved sustained response at baseline and 48 weeks of treatment,and the correlation between baseline serum IL-8 and clinical characteristics was analyzed.Receiver operating characteristic curve(ROC)to evaluate the clinical value of serum IL-8 at baseline in predicting the antiviral efficacy of PEG-IFN-α.Results:Serum level of IL-8 at baseline(181.68±84.43 pg/mL)was significantly lower in patients who achieved sustained response than in patients who achieved non-response(124.81±74.12 pg/mL).After 48 weeks of PEG-IFN-α antiviral treatment,the serum level of IL-8 in patients with continuous response was also significantly decreased,while the serum level of IL-8 in patients who achieved sustained response was not significantly changed.The serum level of IL-8 at baseline was positively correlated with HBsAg,HBeAg and HBV-DNA in both two groups of patients,but the correlations were different.Baseline serum level of IL-8 predicted a sustained response to PEG-IFN-α therapy in HBeAg-positive CHB patients with an area under the curve of 0.711.Conclusion:Serum level of IL-8 at baseline influences the antiviral efficacy of PEG-IFN-α in the treatment of HBeAg-positive CHB patients,and is a potential clinical predictor.
NETL
NSTL
万方数据
